期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

华法林个体差异的遗传药理学因素 被引量：8

The genetic factors of warfarin individual variation
下载PDF
导出
摘要 华法林是临床上的常用药物,其临床反应有很大的个体差异及种族差异,用药剂量可以相差20倍左右,从而限制了其作为抗凝药物的应用。该文简要综述了遗传因素对华法林个体及种族间差异的影响,为临床华法林的个体化治疗提供了一定的理论指导。 Warfarin is one of the most widely used anticoagulants in clinical setting. There are great interindividual differences in both therapeutic efficacy and dose requirement, which greatly limits its application in clinic. This article summarizes the influence of genetic factors on interindividual and interethnic differences of warfarin, providing sufficient guidance for personalized medicine.
作者 张敏 王果 周宏灏
机构地区 中南大学临床药理研究所
出处 《中国药理学通报》 CAS CSCD 北大核心 2008年第7期857-860,共4页 Chinese Pharmacological Bulletin
关键词 华法林 遗传因素 个体化用药 warfarin genetic factors personalized medicine
分类号 R394.6 [医药卫生—医学遗传学] R968.1 [医药卫生—药理学]
  • 相关文献

参考文献31

  • 1Landefeld C S, Beyth R J. Anticoagulant-related bleeding:clinical epidemiology,prediction and prevention [ J ]. Am J Med, 1993,95 (3) :315 -28.
  • 2Loebstein R, Yonath H, Peleg D, et al. Interindividual variability in sensitivity to warfarin-nature or nurture[ J] .? Clin Pharmacol Ther, 2001,70(2) :159 -64.
  • 3Yuan H Y,Chen J J,Lee M T,et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and interethnic differences in warfarin sensitivity[ J]. Hum Mol C, enet,2005, 14(13) :1745 -51.
  • 4D'Andrea G, D'Ambrosio R L,Di Pema P,et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin [ J ]. Blood ,2005 ,105 (2) :645 -9.
  • 5Kimura R, Miyashita K, Kokubo Y, et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients [ J ]. Thromb Res ,2007 ,120 (2) : 181 - 6.
  • 6Bodin L, Verstuyft C, Tregouet D A,et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity [ J ]. Blood, 2005,106( 1 ) :135 -40.
  • 7Schalekamp T, Brasse B P, Roijers J F, et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status:Interaction between both genotypes affects over anti-coagulation [ J ]. Clin Pharmacol Ther ,2006 ,80( 1 ) :13 -22.
  • 8Stubbins M J, Harries L W, Smith G, et al. Genetic analysis of the human cytochrome P450 CYP2C9 locus [ J ]. Pharmacogenetics, 1996,6:429 - 39.
  • 9Taube J, Halsall D, Baqlin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment [ J]. Blood, 2000, 96(5) :1816 -9.
  • 10Higashi M K, Veenstra D L, Kondo L M, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy [ J ]. JAMA ,2002 ,287 ( 13 ) : 1690 - 8.

二级参考文献39

  • 1Umit Yasar,Ingelman-Sundberg et al. Validation of Methods for CYP2C9 Genotyping Frequencies of Mutant Alleles in a Swedish Population[J]. Biochem and Biophys Res Commun,1999,254(3):628-31.
  • 2Shintani M, Ieiri I, Inoue K et al. Genetic polymorphisms and functional characterization of the 5-flanking region of the human CYP2C9 gene: in vitro and in vivo studies[J]. Clin Pharmacol Ther, 2001,70(2):175-82.
  • 3Umit Yasar,Gunnel Tybring et al. Role of CYP2C9 polymorphism in losartan oxidation[J]. Drug Metab Dispos,2001,29(7):1051-6.
  • 4Stephen S, Edward L, Joyce A et al. Goldstein. Regulation of Human CYP2C9 by the Constitutive Androstane Receptor: Discovery of a New Distal Binding Site[J]. Mol Pharmacol,2002,62(3):737-46.
  • 5Cascorbi I, Ackermann E, Sachse C et al. A novel CYP2C9 intron 2 T/C transition and linkage to mutations Leu359 and Cys144 [abstract][J]. Clin Pharmacol Ther,1998,63:198.
  • 6Gerbal-Chaloin S, Pascussi JM, Maurel P et al. Induction of CYP2C genes in human hepatocytes in primary culture[J]. Drug Metab Dispos, 2001,29(3):242-51.
  • 7Takahashi H, Wilkinson GR, Echizen H et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients[J]. Clin Pharmacol Ther, 2003,73(3):253-63.
  • 8Chang TK, Yu L, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: Response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines[J]. Cancer Res, 1997,57(5):1946-54.
  • 9Horsmans Y, Van Den Berge V, Boukaert A, Desager JP. Phenytoin hydroxylation in a healthy Caucasian population: bimodal distribution of hydroxyphenytoin urinary excretion[J]. Pharmacol Toxicol,1997,81(6): 276-9.
  • 10Cuyue Tanga, Magang Shoua, David Rodrigues et al. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics[J]. Pharmacogenetics,2001,11(3):223-35.

共引文献33

同被引文献98

引证文献8

二级引证文献17

中国药理学通报
2008年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部